Can Iovance Biotherapeutics TILt the balance in favour of approval?

Patients who progress on either PD-1 or BRAF/MEK inhibitors are notoriously difficult to treat. Credit: David A Litman/Shutterstock.



  • Iovance Biotherapeutics